共 50 条
Drug Repurposing of Generic Drugs: Challenges and the Potential Role for Government
被引:0
|作者:
Karel H. van der Pol
Mohamad Aljofan
Olivier Blin
Jan H. Cornel
Gerard A. Rongen
Aurélie-Gaëlle Woestelandt
Michael Spedding
机构:
[1] Radboud University Medical Center,Department of Internal Medicine, Radboud Institute for Health Sciences
[2] Nazarbayev University School of Medicine,Department of Biomedical Science
[3] National Laboratory Astana,Institut de Neurosciences des Systèmes
[4] Nazarbayev University,Department of Cardiology, Radboud Institute for Health Sciences
[5] Aix Marseille Université,Department of Cardiology
[6] Inserm UMR 1106,undefined
[7] Radboud University Medical Center,undefined
[8] Northwest Clinics,undefined
[9] Spedding Research Solutions SAS,undefined
来源:
关键词:
D O I:
暂无
中图分类号:
学科分类号:
摘要:
Drug repurposing is the process of identifying a new use for an existing drug or active substance in an indication outside the scope of the original indication. Drug repurposing has important advantages including reduced development time and costs, and potentially large societal healthcare cost savings. However, current generic drug repurposing research faces a number of challenges in obtaining research funds. Furthermore, regardless of the success of a repurposing trial, commercial parties often lack interest in pursuing marketing authorisation for financial reasons, and academic researchers lack the knowledge, time and funding. Therefore, the new indication of a repurposed drug often does not make it ‘on label’. We propose a large increase in public funding for generic drug repurposing research, including funds for the marketing authorisation process when a trial is successful, and a reduction in the regulatory burden of the marketing authorisation process for repurposed generic drugs.
引用
收藏
页码:831 / 840
页数:9
相关论文